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ABSTRACT
We previously showed how key pathways in cancer-related inflammation and 
Notch signaling are part of an autocrine malignant cell network in ovarian cancer. 
This network, which we named the “TNF network”, has paracrine actions within  
the tumor microenvironment, influencing angiogenesis and the immune cell 
infiltrate.
The aim of this study was to identify critical regulators in the signaling 
pathways of the TNF network in ovarian cancer cells that might be therapeutic 
targets. To achieve our aim, we used a systems biology approach, combining data 
from phospho-proteomic mass spectrometry and gene expression array analysis. 
Among the potential therapeutic kinase targets identified was the protein kinase 
Casein kinase II (CK2).
Knockdown of CK2 expression in malignant cells by siRNA or treatment with the 
specific CK2 inhibitor CX-4945 significantly decreased Notch signaling and reduced 
constitutive cytokine release in ovarian cancer cell lines that expressed the TNF 
network as well as malignant cells isolated from high grade serous ovarian cancer 
ascites. The expression of the same cytokines was also inhibited after treatment with 
CX-4945 in a 3D organotypic model. CK2 inhibition was associated with concomitant 
inhibition of proliferative activity, reduced angiogenesis and experimental peritoneal 
ovarian tumor growth.
In conclusion, we have identified kinases, particularly CK2, associated with the 
TNF network that may play a central role in sustaining the cytokine network and/or 
mediating its effects in ovarian cancer.
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INTRODUCTION
Malignant cells generate complex networks of 
constitutively-produced chemokines, their receptors, 
growth factors and inflammatory cytokines, often 
as a consequence of oncogenic mutations [1-5]. 
These networks have paracrine actions in the tumor 
microenvironment impacting on tumor progression and 
spread [6].
Using preclinical models of ovarian cancer, in silico 
analyses of gene expression microarray datasets from over 
500 patient samples and human ovarian cancer biopsies, 
we identified a malignant cell-autonomous cytokine 
network, which includes the stromal cell-derived factor 
CXCL12 and its receptor CXCR4, the inflammatory 
cytokines TNF, IL6, and vascular endothelial growth 
factor (VEGF) [7, 8]. Furthermore, we have demonstrated 
how autocrine CXCL12/CXCR4 signaling sustains this 
cytokine network through induction of TNF and that key 
pathways in cancer-related inflammation and NOTCH 
signaling appear to be part of this autocrine malignant 
cell network [2, 7, 8]. We have shown how this network 
promotes the malignant phenotype through paracrine 
actions on angiogenesis, the stromal signature and the 
immune cell infiltrate in both murine xenograft models 
and ovarian cancer, with an impact on overall survival [2, 
9-12].
The dependency of network genes on TNF was 
demonstrated by their down-regulation in tumour cells 
from patients with advanced ovarian cancer following the 
infusion of anti-TNF antibodies [2, 13]. Therefore, we 
named this observation ‘the TNF network’.
IL-6 is another key regulator of the cytokine network 
in ovarian cancer cells and treatment of ovarian cancer 
patients with an anti-IL6 therapeutic antibody has also 
been shown to have some clinical activity, with periods 
of disease stabilization in some patients, reduced systemic 
cytokine and c-reactive protein levels. However these 
effects were short-lived patients ultimately progressed [9].
The molecular pathways stimulated in malignant 
cells through tumor-promoting cytokines activate 
transcription factors such as NFκB, STAT3, and HIF1α. 
These, in turn, control the production of other chemokines 
and inflammatory mediators [6]. Further studies are 
required to determine the critical signaling nodes or 
pathways in this robust inflammatory cytokine network 
that help maintain the oncogenic phenotype.
Here we have used a systems biology approach, 
integrating genomic and proteomic analyses, to determine 
a hierarchy of critical mediators and pathways associated 
with the TNF network that could be targeted in cancer. 
We identified a number of kinases associated with this 
inflammatory cytokine network and have validated one of 
these kinases, casein kinase 2 (CK2), as a potential driver 
of this network.
RESULTS
Identification of the kinase signaling cascades 
associated with the TNF network
To determine critical mediators in the signaling 
pathways associated with the TNF network, we established 
phosphoproteomic profiles using mass spectrometry 
analysis (LC-MS/MS) in a high TNF network expressing 
ovarian cancer cell line IGROV-1. We analyzed the 
constitutively active kinases in IGROV-1 cells through 
their respective substrates, using Kinase-Substrate 
Enrichment Analysis (KSEA) [25]. Of 45 constitutively 
active kinases, 33 of these showed direct interactions 
with each other according to MetaCore’s Genego 
pathway analysis tool [GeneGo, Inc, St. Joseph, MI] 
(Figure 1A). Many of these kinases are involved in the 
deregulated activation of the MEK/ERK and PI3K/AKT 
pathway, including PDK1 and Casein kinase II, CK2, 
with involvement in chemotherapeutic drug resistance, 
proliferation of cancer initiating cells and angiogenesis 
[27]. We hypothesized that if there are significant 
differences in the activation of specific kinases associated 
with the TNF network, we should detect an increased 
phosphorylation of their respective substrates.
In the past we have shown that the chemokine 
receptor CXCR4 expressed by the malignant cells sustains 
the TNF network through autocrine interaction with 
its ligand CXCL12, as knockdown of this chemokine 
receptor drastically decreased TNF, IL6 and VEGF levels 
in cell culture supernatant of these cells [8]. Therefore 
we generated phosphopeptide signatures by comparison 
of phosphopeptide sites in IGROV-1 cells with cells in 
which the TNF network had been inhibited by shRNA to 
CXCR4. The phosphopeptide intensities obtained from 
the MS data were normalized to the median and log2 
transformed. Phosphopeptides were considered significantly 
different across cell lines at the p<0.05 level by a t-test of 
log transformed data after Benjamini-Hochberg correction 
for multiple hypothesis testing [28]. The results are shown 
as a heatmap (Figure 1B), with yellow indicating lower 
and red indicating higher phosphorylation. Identified 
phosphorylation sites were linked to kinases acting upstream 
using Kinase-Substrate Enrichment Analysis [25].
An examination of the putative upstream kinases 
showed that a number of these were activated in association 
with the TNF network. Among these, PDK1 and CK2 
showed increased activity in high cytokine producing 
IGROV-1 cells compared with its TNF network inhibited 
form (shCXCR4 cells). Since PDK1 and CK2 are involved 
in the regulation of the PI3K/AKT pathway, we have 
confirmed these findings by visualizing the phosphorylation 
of PDK1 and the CK2 specific phosphorylation of AKT 
(Ser129), a phosphorylation site that is often used as a 
marker of CK2 activity by Western blot analysis (Figure 1C) 
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[29, 30]. Phosphorylation of PDK1 (Ser241), PI3K (Tyr458), 
AKT (Ser473 and Ser129), were reduced in the shCXCR4 
cells in which the TNF network has been inhibited. We 
postulated that these associated kinases might be critical 
members of the TNF signalling network and therefore 
potential therapeutic targets.
Conversely, LC-MS/MS analysis showed that 
phosphorylation of PKC delta and its downstream target 
MARCKS were increased in shCXCR4 cells compared 
with IGROV-1 and mock-transfected control cells by LC-
MS/MS analysis. We also detected an increase in phospho-
ERK and the substrates for SRC by LC-MS/MS. However, 
the increased phosphorylation of SRC, when visualized by 
Western blot analysis was subtle (Figure 1C). This might 
be due to the greater sensitivity when LC-MS/MS was 
used for detection.
We previously identified key inflammatory pathways 
and NOTCH signalling in cancer promoting processes by 
Gene Set Enrichment Analysis (GSEA) using the high 
TNF network gene expression signature [2]. Here, we 
Figure 1: Phosphoprotein profiling of human ovarian cancer cell lines. A. A network of putative constitutively active kinases 
in IGROV-1 cells was created using Genego's Metacore pathway analysis tool. Interactions between any two objects are depicted by an 
arrow indicating the direction of interaction. B. Heatmap containing three samples in each group of statistically significantly differentially 
phosphorylated proteins were generated using IGROV-1 and IGROV-Mock transfected versus two independently isolated clones of 
IGROV-1 cells stably transfected with shRNA to CXCR4 (I and II). Increases in phosphorylation are shown as pseudocolour red and 
decreases in yellow. C. Western blot analysis of selected kinases associated with the phenotype of high cytokine expression and downstream 
effect on phospho-STAT3 and NOTCH signaling in malignant cells.
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performed additionally GSEA using the phosphoprotein 
signature identified in these cells (Figure 1B) for process 
and pathways enrichment. Predominant in both analyses, 
with phosphoproteomics and gene expression data, 
NOTCH signalling was the most significantly enriched 
pathway (p<0.0001 and p=0.0003, respectively) in 
association with the TNF network. Furthermore, we 
have shown that NOTCH3 and its ligand, Jagged1, were 
regulated in a STAT3 dependent manner [2]. Again, the 
phosphorylation of STAT3 and the transcription factor 
HES1, downstream of NOTCH signalling, were also 
decreased in shCXCR4 cells compared to the mock-
transfected control (Figure 1C).
Having identified the same important processes and 
pathways with both the proteomic and gene expression 
analyses, we next investigated the key kinases involved in 
regulation of the signaling pathways by exploring the gene 
expression signature of the TNF network further.
Identification of therapeutic targets using a 
gene expression signature of the inflammatory 
phenotype
The interaction of a drug or chemical with a 
biological system can result in a characteristic gene-
expression profile or signature. These signatures can be 
used to connect molecules with similar pharmacological 
or toxicological properties by gene expression signature 
matching. Lamb et al first proposed the Connectivity 
Map (cMap) to make successful connections among small 
molecules, genes, and diseases using genomic signatures 
[31]. Further studies showed that the cMap can be 
exploited to investigate the mode of action (MoA) of novel 
compounds and to identify new potential use for already 
approved drugs (i.e. drug repositioning) [32-34].
To further investigate how to target the TNF 
network, we mapped the gene expression data, using the 
gene expression signatures of CXCR4 knockdown cells 
versus mock-transfected cells, onto the Connectivity 
Map of drugs, in order to identify any compounds having 
an effect on transcription similar to that of the knock-
down of the TNF network. We made use of the Mode of 
Action by Network Analysis (MANTRA) computational 
framework proposed in [32]. Through this tool we 
integrated the profile of differential expression following 
the CXCR4 knock-down into a drug similarity network 
containing all the cMap compounds. This analysis led 
to a network of compounds ‘connected’ to the CXCR4 
knock-down profile of differentially expressed genes 
(Figure 2A and Supplementary Table 1A-F). According 
to the MANTRA tool, these compounds elicit a 
transcriptional response similar to that triggered by 
inhibiting the TNF network by knocking-down CXCR4 
and are clustered in ‘network communities’, statistically 
enriched for certain MoAs.
A summary of these compounds and some of their 
known effects is shown in Figure 2B. Many of these 
compounds have immune modulatory properties. Among 
the identified drugs were luteolin, apigenin (members of 
the same drug community) and resveratrol. One of the 
known targets of this class of drugs is CK2, a protein 
kinase that we identified by phosphoproteomics and 
KSEA to be associated with the TNF network (Figure 1A 
and 1C) [35]. Furthermore, resveratrol has been reported 
to suppress TNF induced activation of NFκB and AP-1, 
and to suppress proliferation, as well as being able to 
overcome chemoresistance through the down-regulation 
of STAT3 [36-38].
We therefore hypothesised that CK2 was a key 
driver of the TNF network and hence specific inhibition of 
this kinase might inhibit the activation of the PI3K/AKT 
pathway and the transcription of downstream targets, such 
as TNF and IL6.
Validation of CK2 as a potential target
In order to validate CK2 as a potential driver or 
mediator of the TNF network, we directly inhibited the 
kinase activity by silencing CK2 expression, using siRNA, 
in two ovarian cancer cell lines, IGROV-1 and SKOV3ip1, 
with similar constitutive TNF, IL6 and VEGF secretion into 
cell culture supernatants. As shown in Figure 3A, almost 
80% knockdown of CK2 mRNA expression was achieved 
after a 48hour transfection with a pool of specific siRNA 
oligonucleotides. The decrease of CK2 activity in both cell 
lines after knockdown with siRNA oligos was monitored 
via its known substrate of AKT (Ser129) by Western blot, 
as shown in Figure 3B. TNF, IL6 and VEGF cytokine 
production was significantly inhibited after transfection 
(Figure 3D) with no effect on cell proliferation (Figure 3C).
In order to confirm the findings observed in our CK2 
knockdown experiments we next determined the effects 
of the specific CK2 inhibitor CX-4945, which is currently 
under investigation in clinical trials [39, 40]. Treatment 
with CX-4945 significantly reduced the constitutive 
release of TNF and IL6 was significantly reduced in 
the cell culture supernatant of five ovarian cancer cell 
lines that were cytokine producers after treatment with 
CX-4945 (Figure 3E) and VEGF production was also 
inhibited in 3/4 parental cell lines (Figure 3E). CX-4945 
inhibited the JAK/STAT3 pathway and protein levels of 
the NOTCH transcription factor HES1 in both IGROV-1 
and SKOV3ip1 cells (Figure 3F). Finally, we observed a 
significant decrease in TNF and IL6 production following 
CK2 inhibition with CX-4945 by ELISA in cell culture 
supernatant of primary cells derived from ascites of four 
high-grade serous ovarian cancer patients (Figure 3G). 
Levels of VEGF were also inhibited in three out of four of 
these primary cancer cell supernatants after treatment with 
CX-4945 (Figure 3G).
As TGFβ1 was not associated with the TNF network 
[2] we included this as an internal negative control. Levels 
of this cytokine did not change significantly as a function 
of CK2 activity (Figure 3D, 3E and 3G).
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Figure 2: Summary of compounds whose transcriptional response is similar to that induced by the knock-down of the 
TNF Network. A. Drug-network based classification using the gene expression signature in shCXCR4 cells. The expression signature of 
cells in which the TNF network has been inhibited is connected to a given drug if the profile of differential expression following the knock-
down is significantly similar to the transcriptional response elicited by that drug in human cancer cell lines. Two drugs are connected to 
each other if their transcriptional response is similar according to the same criteria. Colors indicate groups of densely interconnected nodes 
enriched for a given mode of action, common drug targets or therapeutic application. B. Included are documented effects for each drug in 
light blue and shown in red are the drugs known to target protein kinase CK2. The dark blue bars indicate the extend of similarity between 
the transcriptional responses elicited by the listed compounds and that of the knock-down of CXCR4 (shCXCR4). This is defined as the 
inverse of the distance reported in Supplementary Table 1, and normalised in [0,1]. According to this metric the compound eliciting the most 
similar response to shCXCR4 is 8-azaguanine and CK2 is a recurrent target among those of the top-similar to shCXCR4.
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Figure 3: Effects of specific inhibition of CK2 on the cytokine network in EOC. A. mRNA gene expression of CK2 by real 
time RT-PCR, B. Western blot analysis C. proliferation and D. cytokine production after 48 hours of transient transfection with a pool of 3 
oligos targeting CK2 in IGROV-1 and SKOV3ip1 cells (mean ± SEM, **, P<0.01, *, P<0.05). E. Cytokine and growth factor expression 
levels were measured in cell culture supernatants after 48 hours inhibition of CK2 with 5 μM CX-4945. F. Western blot analysis of 
constitutive CK2 activity by its substrate phospho-Akt (Ser129) and downstream effects after treatment with CX-4945 in a dose dependent 
manner after 24hour treatment with and without CX-4945 (mean ± SEM, ***, P<0.001, **, P<0.01, *, P<0.05). G. Cytokine and growth 
factor expression levels in cell culture supernatants of primary ovarian cancer cells from ascites after 48 hours inhibition of CK2 with 5 
μM CX-4945.
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Apoptotic and anti-proliferative activity of CK2 
inhibition by CX-4945 in vitro
In order to determine the apoptotic activity of CX-
4945 in IGROV-1 and SKOV3ip1 cells, we performed 
Western blot analysis of cleaved PARP. The results 
demonstrate an increase in apoptosis in both ovarian 
cancer cell lines after inhibition of CK2 with CX-4945 in 
a dose dependent manner (Figure 4A).
To assess the effect of CK2 inhibition and anti-
proliferative activity of CX-4945 we performed 
proliferation assays on plastic and in a 3-dimensional 
Figure 4: Effects on apoptosis and proliferation of HGSC cell lines after specific inhibition of CK2 in vitro. Apoptotic 
and proliferative effect of CK2 inhibitor CX-4945 on A. IGROV-1 and SKOV3ip1 cells, in a dose dependent manner by Western blot 
analysis of apoptotic marker cleaved PARP and by cell numbers on plastic over a period of 6 days, and B. representative pictures of H&E 
stained sections in a 3D model after 6 days treatment, respectively. C. Quantification of cell growth inhibition and D. mRNA expression 
of cytokines and growth factors after treatment of SKOV3ip1 cells with CX-4945 in the 3D model (mean ± SEM, **, P<0.01, *, P<0.05).
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(3D), organotypic model of ovarian cancer. Treatment 
of IGROV-1 cells with 5μM CX-4945 over a period of 
6 days showed a modest reduction in proliferation (28%) 
but had no effect on proliferation of SKOV3ip1 cells 
(Figure 4A) on plastic despite the effect seen on apoptosis 
by cleaved PARP by Western blot analysis. These results 
are consistent with previous studies, in which the TNF 
network was inhibited by shRNA to CXCR4 or TNF in 
ovarian cancer cells [2, 8]. However, the proliferation 
of SKOV3ip1 cells were significantly reduced in a 
dose dependent manner after treatment with 1 μM and 
5 μM CX-4945 over the same period of days in a 3D 
organotypic model assay (Figure 4B and 4C). Moreover 
mRNA expression levels of key members of the TNF 
network were also significantly reduced in this model. 
Again, TGFβ1 was included as an internal control and 
mRNA expression levels of this cytokine did not change 
in this setting (Figure 4D).
Specific inhibition of CK2 in vivo
Treatment with CX-4945 (75mg/kg) resulted in a 
significant reduction in tumor growth of the peritoneal 
ovarian cancer xenograft IGROV-1 after 42 days as measured 
by bioluminescence imaging (Figure 5A). The cytokine 
mRNA expression levels of TNF, IL6 and VEGF were 
significantly lower in tumors from CX-4945 treated animals 
(Figure 5B). This correlated with significantly decreased 
vascular area of size-matched tumor deposits compared 
with the control group and reduced proliferative index of 
the malignant cells as assessed by immunohistochemistry for 
Ki67 (p<0.001) (Figure 5C and 5D).
Figure 5: Effects of specific inhibition of CK2 on xenograft growth in vivo. A. Quantification of bioluminescence from tumors 
(n=6 mice per group) at different time points (*, P <0.05) and B. mRNA expression of cytokines in primary tumors (n=3) by real time 
RT-PCR after treatment with CK2 inhibitor CX-4945. C. Representative pictures of confocal images (magnification x20) from tumors 
following injection of TRITC-lectin and Ki67 stained paraffin sections by immunohistochemistry after 42 days treatment with 75mg/kg 
CX4945. D. Quantification vascular area and proliferative index. Columns, mean in each group in 10 randomly selected areas of tumor 
sections (mean ± SEM, ***, P<0.001).
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DISCUSSION
Malignant cells from many different cancer types 
constitutively produce inflammatory cytokines and 
chemokines that are important in tumor growth and cancer 
progression, TNF and IL-6 being the most commonly 
reported [41, 42]. The mediators are co-regulated in 
complex networks and are downstream of many common 
oncogenic mutations, but key nodes in intracellular 
signaling networks that control this constitutive production 
are not clearly defined [3, 5]. The approach described 
here has allowed us to identify casein kinase II, CK2, as 
a regulator and potential intracellular target to inhibit the 
inflammatory phenotype in cancer.
To conduct this study we used cancer cell lines that 
produced high levels of TNF network proteins. It is now 
clear that the term ‘ovarian’ cancer refers to at least five 
distinct diseases all of which grow and spread within the 
peritoneal cavity and ovary [43]. These five cancers; low-
grade serous, mucinous, endometrioid, clear cell and high-
grade serous, are now defined by their genomic profile 
and biomarkers. This concept has major implications 
for human cell line models of ovarian cancer as recent 
analysis of commonly used ovarian cancer cell lines, 
including some of those used in this paper, has questioned 
which type of ovarian cancer they may represent [14, 15]. 
Some of the cell lines we have used, as well as the primary 
malignant cells, are derived from the most lethal and 
common form of ovarian cancer, high-grade serous. Clear 
cell carcinoma cells also produce high levels of IL-6 [15] 
and other TNF network members (our unpublished data). 
Therefore we believe that our analysis of the regulation of 
the TNF network by CK2 is relevant to several different 
epithelial cancer types and may also be relevant to other 
malignancies such as myeloma [44].
CK2 is a highly conserved constitutive active 
serine/threonine protein kinase that regulates multiple 
pathways frequently activated in cancer including the 
PI3K/AKT, RB, and WNT signaling cascade [45, 46]. 
Through phosphorylation of more than 300 substrates, it 
is involved in DNA replication, gene transcription, signal 
transduction, cell growth and apoptosis [47, 48]. Although 
CK2 is overexpressed in myeloma [49], leukemia [50] 
and solid tumors including lung, kidney and head and 
neck cancers [46] it is not per se a classical oncogene. 
However, CK2 was shown to be essential in maintaining 
the phenotype of inflammatory breast cancers [39, 40] and 
has been recently described as therapeutic target in PTEN-
deficient tumors [30]. Even though PTEN is only mutated 
in about 7% of HGS ovarian cancers, PTEN deletion or 
downregulation is much more frequent than to be thought 
and therefore its impact on the PI3K/AKT pathway might 
be crucial in up to 50% of HGS ovarian cancers [51].
We validated CK2 as a potential driver of the 
inflammatory phenotype in ovarian cancer cells using 
siRNA and the selective small molecule inhibitor CX-
4945 of CK2 expression levels and activity respectively. 
Knockdown of CK2 expression in malignant cells by 
siRNA or treatment with the specific CK2 inhibitor CX-
4945 reduced significantly cytokine expression in vitro and 
decreased Notch signaling. Even though we did not see an 
anti-proliferative effect by inhibition of the kinase with 
neither siRNA oligos nor specific inhibitor CX-4945 on 
plastic, there was a significant reduction of cell numbers 
in a 3D organotypic model of ovarian cancer with CX-
4945. The expression level of TNF, IL6 and VEGF was 
also inhibited after treatment with CX-4945 in this model. 
Therefore it is possible that these cytokines are inducing 
other cytokines and growth factors in the fibroblast and 
mesothelial cells to stimulate tumor growth. Hence, 
inhibition of CK2 by CX-4945 might lead to the decrease 
in cell numbers by blocking the paracrine action of the 
cytokines on stromal cells in 3D cultures. Proliferative 
activity of the malignant cells was also inhibited by CX-
4945 in vivo therefore this might be a key mechanism in 
peritoneal ovarian tumor growth.
Surprisingly, we also noticed an increase in activity 
of PKC and the tyrosine kinase SRC after inhibition of the 
TNF network (Figure 1C). In general, kinase inhibitors 
have had limited success in cancer treatment as single 
agent therapies, despite the biological effects achieved in 
preclinical studies. The reasons may be that cancer cells 
present an enormous genetic heterogeneity and circumvent 
their action through a robust signaling network with a 
reciprocal regulatory feedback mechanism. Therefore, 
PKC and/or SRC are maybe promising therapeutic targets 
in combination with CK2 inhibition in ovarian cancer and 
we will investigate this in future studies.
In conclusion, we have identified kinases, 
particularly CK2, associated with the TNF network that 
may play a central role in sustaining the cytokine network 
and/or mediating its effects in ovarian cancer.
MATERIALS AND METHODS
Ovarian cancer cells
Ovarian cancer cell lines SKOVip1, IGROV-1, 
CAOV-3, and PEO1 were selected for high expression 
levels of key members of the TNF network and cultured 
as described [8]. All cell lines have undergone 16 loci 
STR authentication (LGC Standards, London, UK). The 
cells were cultured in RPMI 1640 10% FCS, routinely 
tested for mycoplasma contamination and only passaged 
four times before new stocks were recovered from liquid 
nitrogen stores. Recent studies identified CAOV3 and 
PEO1 as HGSC cell lines. However, the widely used cell 
lines SKOV-3 and IGROV-1 were implicated as not being 
representative of the major HGSC subtype [14-16]. All 
primary cells were isolated from human ascites collected 
from ovarian cancer patients at St. Bartholomew’s 
hospital. All samples were taken under the guidelines 
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of the Human Tissue Authority Act 2004 and only from 
patients whom had given prior consent under the Research 
Ethical Committee Project reference 10/H0304/14.
Transfection of IGROV-1 and SKOV3ip1 cells
Cells were transfected with the ON-TARGET 
plus SMART pool of oligos targeting CSNK2A1 gene 
expression using Lipofectamin as described previously 
[8]. SiCONTROL non-targeting siRNA pool served as 
control.
Western blotting
Cell extract (15μg) was run on an SDS 10% 
acrylamide gel and transferred to a nylon membrane. 
The membrane was blocked for 1hour (4°C in PBS with 
0.1% Tween and 10% milk powder) and probed overnight 
using anti-phospho-PDK1 (3061, Cell Signaling, UK), 
PDK1 (3062, Cell Signaling, UK), phospho-PI3K (4228, 
Cell Signaling, UK), PI3K (4255, Cell Signaling, UK), 
phospho-Akt473 (sc-9271, Santa Cruz, UK), Akt473 
(4685, Cell Signaling, UK), phoshor-STAT3 (D3A7, 
Cell Signaling, UK), STAT3 (4904, Cell Signaling, UK), 
anti-Casein kinase 2 (06-873, Millipore, UK), phospho-
Akt129 (AP3020, Cambridge Biosience, UK), and HES1 
(H140, Santa Cruz, UK). A horseradish peroxidase-
conjugated secondary antibody was used for detection 
(1:2,000) dilution at room temperature for 1 hour. Protein 
concentration equivalence was confirmed by anti-β-actin 
antibody.
Cytokine ELISA
Cells were plated at 3 x 105 cells/well, cell culture 
supernatants removed after 48 hours of culture and 
cytokine concentrations measured using Quantikine® 
ELISA kits (R&D Systems) or Cytokine analyses with 
ECL assays were done according to man-manufacturer’s 
instructions (MSD human IL6, TNF, IL8, and VEGF 
multiplex microplate, N45CA-1).
RNA extraction and real time quantitative 
RT-PCR
RNA was extracted using Tri Reagent (Sigma), 
and treated with 10 U DNase (Pharmacia, Milton 
Keynes, UK). DNase treated RNA (2 μg) was reverse 
transcribed with M-MLV reverse transcriptase (Promega, 
Southampton, UK). Multiplex real-time RT-PCR analysis 
was performed using pre-made TaqMan® probes (FAM) 
and 18s rRNA (VIC) specific primers and probes with the 
ABI PRISM 7700 Sequence Detection System instrument 
and software (PE Applied Biosystems, Warrington, UK). 
Expression values were normalized (∆Ct) to 18s rRNA by 
subtracting the cycle threshold (Ct) value of 18s rRNA 
from the Ct value of the experimental value.
Phosphoproteomics
Mass spectrometry based phosphoproteomics was 
performed as described before with minor modifications 
[17, 18]. Briefly, cells were lysed in urea lysis buffer (8M 
urea in 20 mM HEPES pH 8.0) containing phosphatase 
inhibitors (1 mM Na3VO4, 1 mM NaF, 1 mM β-glycerol 
phosphate, 1.25 mM sodium pyrophosphate). After 
centrifugation (20,000g for 5 min at 5°C), protein 
levels quantified by Bradford analysis. A sample aliquot 
containing 500 μg of protein was diluted to a final volume 
of 1 ml in denaturing buffer and 4.1 mM dithiothreitol and 
8.3 mM iodoacetamide sequentially added for 15 min at 
room temperature in the dark. After dilution of samples 
to a final concentration of 2 M urea using 20 mM HEPES 
(pH 8.0), proteins were digested with TPCK-Trypsin (20 
TAME units/mg) for 16 h at 37°C. The resultant peptide 
solutions desalted by solid-phase extraction with Oasis 
reversed phase solid phase extractions columns (Waters 
UK ltd, Manchester, UK) following the manufacturer’s 
instructions with modifications. Elution solution contained 
60% acetonitrile (ACN), 2M glycolic acid, 5% TFA.
Phosphopeptide extraction and analysis
Phosphopeptides were enriched by TiO2 
chromatography as described by Larsen [19] with the 
modifications described elsewhere [17] and analysed in a 
LC-MS/MS system in random order to remove potential 
batch effects. Phosphoprotein separation was performed 
in a nanoflow ultra-high pressure liquid chromatography 
system (nanoAcquity, Waters) using a BEH 100 μm x 100 
mm column (Waters) and a binary mobile phase gradient 
with 0.1% formic acid in LC-MS grade water (A) 0.1% 
formic acid in LC-MS grade acetonitrile (solution B). 
Gradients used were as follows: 1% B for 5 min, 1% B to 
35% B over 100 min, a 5 min wash at 85% B and a 7 min 
equilibration step at 1% B. Gradient elution was at 400 
nl/min. An LTQ-Orbitrap XL mass spectrometer (Thermo 
Fisher Scientific, Hemel Hempstead, UK) acquired full 
scan survey spectra (m/z 350–1600) with a resolution 
of 30,000 at m/z 400 and the top five most abundant 
multiply charged ions present in each survey spectrum 
were fragmented by collision-induced dissociation 
(CID, normalized collision energy 35%) with multi stage 
activation (MSA). A dynamic exclusion of 40 sec and 
mass window of 10 ppm was used.
Identification and quantitation of 
phosphopeptides
Identification and quantification of phosphopeptides 
from LC-MS/MS data was as described before [20, 21]. 
Briefly, Mascot Distiller 2.3.2 was used to smoothen and 
centroid the MS/MS data and to generate peak list files 
which were searched against the human sequence library 
in the SwissProt database (version 2010_03 containing 
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23,000 entries, http://expasy.org/sprot/) using the Mascot 
search engine [22]. Search parameters included: trypsin 
as digestion enzyme with two missed cleavages allowed, 
carbamidomethyl (C) as fixed modification, and Pyro-
glu (N-term), Oxidation (M) and Phospho (STY) as 
variable modifications. A mass tolerance of ± 7 ppm for 
the precursor ion and ±800 mmu for fragment ions was 
allowed. Hits were considered significant when they had 
an Expectation value of < 0.05 (as returned by Mascot). 
False discovery rates were ~0.02 as determined by decoy 
database searches. Sites of modification were reported 
when the Mascot delta score was greater than 10 [23]; 
otherwise site assignment was deemed ambiguous and 
are reported as gene name followed by phosphorylation 
site within the protein sequence and charge of the 
measured ion. Phosphopeptides identified by Mascot 
above the statistically significant threshold were selected 
for quantification with Pescal [18, 24]. The resulting 
quantitative data were parsed into Excel files for further 
normalization and statistical analysis. Phosphopeptide 
intensities were normalized to the total chromatogram 
intensity and to the mean value across samples. 
In order to infer kinase activity from quantitative 
phosphoproteomics data, phosphorylation sites were 
linked to kinases acting upstream using Kinase-Substrate 
Enrichment Analysis [25].
3-dimensional (3D) organotypic model
The method was used as previously described 
[26] with minor modifications. All primary cells were 
isolated from human omentum samples collected from 
surgery on ovarian cancer patients at St. Bartholomew’s 
hospital. Samples were taken under the guidelines 
of the Human Tissue Authority Act 2004 and only 
from patients whom had given prior consent under 
the Research Ethical Committee Project reference 10/
H0304/14. For the 3D Omental model construction, a 
collagen mix was made up on ice constituting one part 
10X RPMI-1640 (powder dissolved in distilled water 
and Sodium Bicarbonate; Sigma, R6504), one part 
0.33M Sodium Hydroxide, (Sigma, S-8045), one part 
FBS, and seven parts Rat-tail Collagen, Type 1, (BD 
Biosciences, 354236). 50μL of the mix was added to 
each well of a 24 well Corning Transwell-Clear, plate 12 
inserts, 3μm pore size, 6.5mm diameter, (Fisher, TKT-
525-090R), and allowed to set for 30 minutes. 50,000 
human embryo fibroblasts (HEF) were mixed into 50μL 
of the collagen mix per well, and allowed to set on top 
of the pre-set layer. 500μL and 100μL of full medium 
were placed in the bottom and top part of the transwell 
respectively and left in culture for 24 hours. 40,000 
human primary mesothelial cells (HPMC) were then 
seeded in 100μL of full medium to the top part of each 
transwell and left to culture for 24 hours. 50,000 ovarian 
cancer cells were then seeded in 100μL of full medium 
to the top part of each transwell and left to culture for 
a further 24 hours. The top and bottom compartment of 
each transwell was washed in PBS, and full medium 
was placed in the bottom compartment and serum-free 
medium was placed in the top compartment to generate 
a serum concentration gradient. The models were left 
in culture for 14 days with and without CK2 specific 
inhibitor CX4945 (Cylene).
Growth of human ovarian cancer cell lines 
in vivo
BALB/C nude female mice (Charles River, UK) 6-8 
weeks of age, were used in all experiments. Mice were 
housed in sterile individually ventilated cages (IVC) at 
20°C. Mice were injected i.p. with 1 x 107 IGROV-1/
Luciferase cells, observed daily for tumor growth and 
were killed when peritoneal swelling reached the endpoint 
stated in our Home Office licence PPL 70/6578 (20% 
increase in abdominal girth). Paraffin embedded sections 
were stained with an anti-Ki67 antibody (SC-7846, Santa 
Cruz Biotech).
Bioluminescence imaging
Mice were injected i.p. with 150 μg/g bodyweight 
D-luciferin in PBS, and bioluminescence imaging 
with a charge-coupled device (CCD) camera (IVIS, 
Xenogen, Alameda, CA) was initiated 10 minutes after 
injection (Smith et al. 2004). Bioluminescence images 
were obtained with a 15 cm field of view (FOV), 
binning (resolution) factor of 8, 1/f stop, and open 
filter with an imaging time of 5 seconds. Data were 
analyzed using Living Image software (also Xenogen) 
and are presented as relative light units (RLU) of light 
emission/s/cm2 from ventral imaging and photon flux 
from a ROI drawn over a mouse that was not given an 
injection of luciferin.
Quantification of tumor blood vessels
To visualize the architecture of blood vessels, 
animals were anesthetised with isoflurane, injected 
with TRITC-conjugated Lycopersicon Esculentum 
(tomato lectin) (100 μl, 2 mg/ml, Vector Laboratories, 
Burlingame, CA) via the tail vein 3 min before animals 
were perfused with 4% paraformaldehyde. Following 
fixation overnight in 4% PFA resected primary tumors 
were cryoprotected in 12%, 15%, and 18% sucrose for 
1hour each. Tumors were subsequently snap-frozen in 
O.C.T. compound (Sankura Finetek, Torrance, CA) and 
sectioned at 50 μm intervals. Vessels were visualized 
using confocal microscopy (Zeiss LSM S10 META) 
and microvessel density quantified with ImagePro Plus 
software (Image-Pro plus, Media Cybernetics, Silver 
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Spring, MD). Microvessel density was expressed as 
mean percentage of microvessel surface area.
Statistical analysis
Statistical analysis of in vitro and animal 
experiments used one-way ANOVA or unpaired T-test with 
Welch correction (GraphPad Prism version 4 Software, 
San Diego, CA).
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